Published in final edited form as:

J Med Chem. 2010 December 23; 53(24): 8642–8649. doi:10.1021/jm1010447.

Removal of the 26-methyl group from 19-nor-1 α ,25-dihydroxyvitamin D₃ markedly reduces *in vivo* calcemic activity without altering *in vitro* VDR binding, HL-60 cell differentiation and transcription

Pawel Grzywacz¹, Grazia Chiellini¹, Lori A. Plum¹, Margaret Clagett-Dame¹, and Hector F. DeLuca^{1,*}

¹Department of Biochemistry, University of Wisconsin-Madison, 433 Babcock Drive, Madison, WI 53706, USA

Abstract

Twelve new analogs of 19-nor-1 α ,25-dihydroxyvitamin D₃ (**5**, **6**, **7**, **8**, **9**, **10**, **11**, **12**, **13**, **14**, **15** and **16**), were prepared by convergent syntheses, employing the Wittig-Horner reaction. The necessary Grundmann-type ketones (**45**, **46**, **47** and **48**), possessing fixed configurations of the hydroxyl group at C-25, were obtained by a multi-step procedure from commercial vitamin D₂ and enantiomers of 1,3-butanediol (**23** and **24**). We have examined the influence of removal of one of the methyl groups located at C-25 on the biological *in vitro* and *in vivo* activity. The *in vivo* tests showed that the synthesized vitamin D compounds (**5**, **6**, **7**, **8**, **9**, **10**, **11**, **12**, **13**, **14**, **15** and **16**) exhibit reduced calcemic activity both in bone and in the intestine. But *in vitro* potency of 2-methylene and 2 α -methyl compounds (**5**, **6**, **7**, **8**, **9**, **10**, **13** and **14**) remained similar or enhanced compared to that of 1 α ,25-(OH)₂D₃.

Introduction

1 α ,25-Dihydroxyvitamin D₃ (1 α ,25-(OH)₂D₃[†], calcitriol, **1**; Figure 1), the active form of vitamin D₃, is one of the primary biological regulators of calcium and phosphorus homeostasis in humans and animals. 1–4 Its important biological effects include the inhibition of proliferation and increased differentiation of various malignant cells, 5–8 as well as suppression of the autoimmune disease.⁹ Such a broad range of diverse functions suggests enormous therapeutic potential of vitamin D compounds.¹⁰ However, the application of these compounds has been limited by the danger of hypercalcemia. Structural modifications of the vitamin D molecule have led to a search for new analogs that exhibit reduced calcemic potency and selective actions.¹¹ In 2007, we reported the biological properties of two 2-methylene-19-nor analogs (**2** and **3**) in which the side chains were modified at C-25.^{12–13} Removal of the 25-hydroxy group from compound **4**¹⁴ led to reduced activity *in vitro*, but *in vivo* calcemic potency remained unchanged likely because of *in vivo* 25-hydroxylation. Methyl replacement of the 25-hydroxy group in **4** reduced the

*To whom correspondence should be addressed: Dr. Hector F. DeLuca, Department of Biochemistry, University of Wisconsin, 433 Babcock Drive, Madison, WI 53706-1544; Telephone: 608-262-1620; Fax: 608-262-7122; deluca@biochem.wisc.edu.

Supporting Information **Available:** Purity criteria, spectral and X-ray data of the synthesized compounds; representative figures with either the competitive binding curves or dose-response curves derived from the binding, cellular differentiation and transcriptional assays of the vitamin D analogs (**5**, **6**, **7**, **8**, **9**, **10**, **11**, **12**, **13**, **14**, **15** and **16**). Ordering information is given on any current masthead page.

overall potency but retained bone selectivity (compound **3**). These results suggest that a possible approach to reducing calcemic activity might be the elimination of the methyl groups surround C-20. We now report several new analogs produced by removing the 26-methyl group from the 2-carbon-substituted 19-nor-1 α ,25-dihydroxyvitamin D₃ and its 20S isomer.

Results and Discussion

Chemistry

The synthetic strategy for new analogs (**5**, **6**, **7**, **8**, **9**, **10**, **11**, **12**, **13**, **14**, **15** and **16**) was based on the Lythgoe type Horner-Wittig olefination reaction,¹⁵ which was successfully utilized by us earlier for preparation of the vitamin D compounds (**2** and **3**).¹² This approach required using new Grundmann-type ketones (**45**, **46**, **47** and **48**) (Scheme 1), which we intended to prepare from the known alcohols (**17** and **18**) and commercially available enantiomers of 1,3-butanediols (**23** and **24**) (Scheme 2). In order to obtain C,D-ring ketones (**45**, **46**, **47** and **48**) we employed the Wittig reaction¹⁶ to attach new side chains to the C,D-ring aldehydes (**19** and **20**). Commercial (*S*)- and (*R*)-1,3-butanediols (**23** and **24**), respectively, appeared to be suitable starting materials for construction of the side chains, possessing fixed configurations of the hydroxyl group at C-25 (steroidal numbering). Selective tosylation of primary hydroxy groups of diols (**23** and **24**), followed by a triethylsilyl protection of secondary hydroxy groups provided corresponding tosylates **25** and **26** (Scheme 2). These compounds (**25** and **26**) were converted into primary iodides **27** and **28**, which were treated with triphenylphosphine in acetonitrile under reflux. The triethylsilyl ethers appeared to be unstable under these reaction conditions, which led to the generation of hydroxyphosphonium iodides **21** and **22**. Despite the loss of the protective group, we used the salts **21** and **22**, based on the efficient application of the analogous salt in the synthesis of the Windaus-Grundmann ketone as described by Mourino.¹⁷

The C,D-ring aldehydes **19** and **20** were obtained by the oxidation of the corresponding alcohols **17** and **18**, which were previously prepared in our laboratory from commercial vitamin D₂.¹² The Wittig reaction between compounds **19** and **20** and ylides, generated from the hydroxyphosphonium iodides **21** and **22** by *n*-butyllithium, provided only olefinic products (**29**, **30**, **31** and **32**) with the *E*-geometry of the introduced double bond. The catalytic hydrogenation of the compounds (**29**, **30**, **31** and **32**) furnished the tertiary alcohols **33**, **34**, **35** and **36**, which were protected as *tert*-butyldimethylsilyl ethers (**37**, **38**, **39** and **40**). The removal of the benzoyl group under basic conditions gave the secondary alcohols **41**, **42**, **43** and **44**, which were subjected to catalytic oxidation with tetrapropylammonium perruthenate¹⁸ in the presence of 4-methylmorpholine N-oxide and afforded the expected ketones **45**, **46**, **47** and **48**. The Horner-Wittig reaction between the corresponding C,D-fragments (**45**, **46**, **47** and **48**) and the anion, generated from the phosphine oxide **49** by phenyllithium, produced the protected vitamin D compounds **50**, **51**, **52** and **53** (Scheme 3). The silyl-protective groups were cleaved in the presence of hydrofluoric acid and after the final purification by HPLC, the target vitamin D analogs **5**, **6**, **7** and **8** were obtained. The X-ray analysis of a single-crystal of the compound **5** (Figure 2) confirmed the stereochemistry at C-25 as (25*S*). The homogenous catalytic hydrogenation of 2-methylene compounds **5**, **6**, **7** and **8**, in the presence of tris(triphenylphosphine)rhodium(I) chloride, provided approximately an equimolar mixture of 2-methyl-19-norvitamins, which were easily separated by HPLC.

Biological evaluation

A standard set of *in vitro* assays were conducted with all twelve compounds (**5**, **6**, **7**, **8**, **9**, **10**, **11**, **12**, **13**, **14**, **15** and **16**) to ascertain receptor binding, cell differentiation and gene

transcription activity. Table 1 shows the results of the competitive VDR binding assays compared to the natural hormone **1** and to 2-methylene-19-nor-(20*S*)-1 α ,25-dihydroxyvitamin D₃ (**4**). No remarkable differences in binding to the receptor were noted except with (20*R*)-2 β -methyl compounds **11** and **15**. The VDR binding affinities of these analogs are approximately one log less than those of the native hormone **1**, or analogs possessing 2-methylene (**4**, **5**, **6**, **7**, **8**) or 2 α -methyl (**9**, **10**, **13**, **14**) groups.

The results of the HL-60 cell differentiation assays are depicted in Table 1. In these assays, cells were given one dose of the indicated amounts and after four days, the extent of differentiation assessed by incubating the cells with a substrate (nitro blue tetrazolium) which is reduced by the cells if they have differentiated into monocytes. Although (25*R*) analogs demonstrate slightly more activity than (25*S*) compounds, the configuration of the 25-hydroxy group exerts a small impact on the overall potency in cell differentiation. Two (20*S*,25*R*) compounds **8** and **14**, possessing 2-methylene or 2 α -methyl group respectively, have differentiation activity 20 times higher than 1,25(OH)₂D₃ **1**, but approximately 0.8 times lower than parent compound **4**. Four (20*R*) compounds (**5**, **7**, **9**, **13**) and two (20*S*, 25*S*)-analogs (**6**, **10**) exhibit the next highest activity in this assay, which is approximately similar to that observed with the native hormone **1**. Not surprisingly, the derivatives **11**, **12**, **15** and **16**, containing a 2 β -methyl substituent, have the lowest activities, 3-35 times lower than 1,25(OH)₂D₃ **1**.

The pattern of potencies in *in vitro* transcription assays is shown in Table 1. Similar to that observed in the HL-60 cell differentiation assays, (25*R*) compounds demonstrate higher transcriptional potency than in the case of (25*S*) analogs. This difference is more noticeable in the case of the (20*S*) compounds. In this cell-based assay, two (20*S*,25*R*) compounds **8** and **14** express the highest transcriptional potency. The activity of the other 2-methylene and 2 α -methyl analogs (**5**, **6**, **7**, **9**, **10**, **11**, **12**, **13**) is similar to that observed with natural hormone **1**. Consistent with the other two *in vitro* assays, the derivatives possessing a 2 β -methyl group **11**, **12**, **15** and **16** possess the lowest transcriptional activities.

In vivo biological activities are shown in Figure 3 and Table 2. Both intestinal calcium transport and bone calcium mobilization were measured in the same rats made vitamin D-deficient prior to administering any of the experimental compounds. A rise in blood calcium levels reflect the ability of an analog to stimulate the mobilization of bone calcium because the animals are fed a diet essentially devoid of calcium. Analog activity in the intestine was assessed *ex vivo* by analyzing calcium transport in the everted gut sac preparation. Figure 3 highlights the fact that all of the analogs have low bone mobilizing activity. The most potent compound **8** is at least 25 times (21060 pmol/780 pmol) less active than the native hormone **1** *in vivo*, yet analog **8** is much more potent than 1,25(OH)₂D₃ **1** in causing cellular differentiation and stimulating *in vitro* 24-OHase transcription. The order of bone calcium mobilizing activity of the 19,26-dinor compounds (**5**, **6**, **7**, **8**, **9**, **10**, **11**, **12**, **13**, **14**, **15** and **16**) parallels that observed *in vitro*, among them 2-methylene and 2 α -methyl analogs of (20*S*) configuration **6**, **8**, **10**, **14** being the most potent. It's worth noting that (25*R*) diastereoisomers are more potent on bone.

Table 2 summarizes the results obtained from the intestinal calcium transport assays. In contrast to the bone, the (20*S*,25*R*) compound **8** has similar activity to the native hormone **1** or the parent analog **4** in the intestine. The remainder of the compounds has reduced intestinal calcium transport activity, among them 2 β -methyl compounds **11**, **15**, **16** have the lowest in particular when coupled with a (20*R*) configuration.

Conclusions

The present study clearly shows that removal of one methyl from C-25 of the 19-norvitamin D₃ analogs (**5**, **6**, **7**, **8**, **9**, **10**, **11**, **12**, **13**, **14**, **15** and **16**) markedly reduces the calcemic activity derived from either bone or intestine. On the other hand, the lack of the same methyl group has little impact on receptor binding, HL-60 differentiation and *in vitro* transcription. The exceptions are the 2 β -methyl analogs that are virtually devoid of any activity. In the case of the 20*S* compounds analogs (**6**, **8**, **10**, **14**), the *in vitro* activity is increased by removal of the methyl at C-25 accompanied by a 25*R* configuration. Thus, the most potent of the 19,26-dinorvitamin D series are (20*S*,25*R*)-2-methylene and 2 α -methyl analogs **8** and **14**, respectively. In general, 25*R*-hydroxy analogs exhibit higher potency, measured both *in vitro* and *in vivo*, than 25*S* diastereoisomers. The greatly reduced calcemic activities of the presented compounds (**5**, **6**, **7**, **8**, **9**, **10**, **13**, **14**) coupled with their ability to promote differentiation make them drug candidates for treatment of secondary hyperparathyroidism of renal failure and possibly, certain cancers.

Experimental Section

Chemistry

Melting points (uncorrected) were determined on a Thomas-Hoover capillary melting-point apparatus. Optical rotations were measured in chloroform or methanol using a Perkin-Elmer Model 343 polarimeter at 22 °C. Ultraviolet (UV) absorption spectra were recorded with a Perkin-Elmer Lambda 3B UV-VIS spectrophotometer in ethanol or hexane. ¹H nuclear magnetic resonance (NMR) spectra were recorded in deuteriochloroform, acetone-d₆ or methanol-d₄ at 400 and 500 MHz with Bruker Instruments DMX-400 and DMX-500 Avance console spectrometers. ¹³C nuclear magnetic resonance (NMR) spectra were recorded in deuteriochloroform, acetone-d₆ or methanol-d₄ at 100 and 125 MHz with the same Bruker Instruments. Chemical shifts (δ) in parts per million are quoted relative to internal Me₄Si (δ 0.00). Numbers in parentheses following the chemical shifts in the ¹³C NMR spectra refer to the number of attached hydrogens as revealed by DEPT experiments. ³¹P nuclear magnetic resonance (NMR) spectra were recorded at 162 MHz with Bruker Instruments DMX-400 Avance console spectrometer in methanol-d₄. Chemical shifts (δ) in parts per million are quoted relative to external H₃PO₄ (δ 0.00). Electron impact (EI) mass spectra were obtained with a Micromass AutoSpec (Beverly, MA) instrument. High-performance liquid chromatography (HPLC) was performed on a Waters Associates liquid chromatograph equipped with a Model 6000A solvent delivery system, Model U6K Universal injector and Model 486 tunable absorbance detector. The known alcohols **17** and **18** were prepared according to the published procedure. 12 THF was freshly distilled before use from sodium benzophenone ketyl under argon. A designation “(volume + volume)”, which appears in general procedures, refers to an original volume plus a rinse volume.

All final vitamin D analogs synthesized by us gave single sharp peaks on HPLC and they were judged at least 99.5% pure. Two HPLC systems (straight- and reversed-phase) were employed as indicated in Table 3 (Supporting Information).

General Procedure for the Synthesis of Compounds 19 and 20

To a solution of the alcohol **17** or **18** (1 eq), triethylamine (5 eq) in anhydrous methylene chloride and anhydrous DMSO, the sulfur trioxide pyridine complex (6 eq) was added at 0 °C. The reaction mixture was stirred under argon at 0 °C for 1 h and then it was concentrated under reduced pressure. The crude mixture was diluted with ethyl acetate, washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (2→5% ethyl acetate/hexane) to give the aldehyde **19** or **20**.

General Procedure for the Synthesis of Compounds 25 and 26

To a stirred solution of 1,3-butanediol **23** or **24** (1 eq), DMAP (0.02 eq) and triethylamine (3 eq) in anhydrous methylene chloride, *p*-toluenesulfonyl chloride (1.2 eq) was added at 0 °C. The reaction mixture was stirred at 4 °C for 22 h. It was diluted with methylene chloride, washed with water, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica (20→50% ethyl acetate/hexane) to give a tosylate.

To a stirred solution of tosylate (1 eq), 2,6-lutidine (1.1 eq) in anhydrous methylene chloride, triethylsilyl trifluoromethanesulfonate (1 eq) was added at -50 °C. The reaction mixture was allowed to warm to room temperature (4 h) and stirring was continued for an additional 20 h. It was diluted with methylene chloride, washed with water, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography on silica (3% ethyl acetate/hexane) to give the product **25** or **26**.

General Procedure for the Synthesis of Compounds 27 and 28

To a stirred solution of the tosylate **25** or **26** (1 eq) in anhydrous acetone (50 mL), potassium iodide (5.5 - 6.3 eq) was added. The reaction mixture was refluxed for 10 h. Water (30 mL) was added to dissolve salts and the mixture was extracted with ethyl acetate. Combined organic phases were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica (3% ethyl acetate/hexane) to give the iodide **27** or **28**.

General Procedure for the Synthesis of Compounds 21 and 22

To a stirred solution of the iodide **27** or **28** (1 eq) in anhydrous acetonitrile (50 mL), triphenylphosphine (3 eq) was added. The reaction mixture was refluxed for 2 days. The solvent was evaporated under reduced pressure to give the solid. Ethyl acetate (50 mL) was added, the mixture was stirred at room temperature for 4 h and the solvent was removed by filtration. The solid was stirred again with ethyl acetate for 1 h and the solvent was removed. After drying, the pure phosphonium iodide **21** or **22** was obtained.

An alternative to this procedure is to dissolve the solid mixture of the phosphonium iodide and triphenylphosphine in methylene chloride and reprecipitate the salt by adding diethyl ether.

General Procedure for the Synthesis of Compounds 29, 30, 31 and 32

To a stirred suspension of the phosphonium salt **21** or **22** (3 eq) in anhydrous THF (5 mL), *n*-butyllithium (4.5 - 6 eq) was added at -20 °C. The solution was stirred at -20 °C for 1 h and it turned deep orange. A precooled solution of aldehyde **19** or **20** (1 eq) in anhydrous THF (1+1 mL) was added and the reaction mixture was stirred at -20 °C for 4 h and at room temperature for 18 h. The reaction was quenched with water and the mixture was extracted with ethyl acetate. Combined organic phases were washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica (5→10% ethyl acetate/hexane) to give the product **29**, **30**, **31** or **32**.

General Procedure for the Synthesis of Compounds 33, 34, 35 and 36

To a solution of the olefin **29**, **30**, **31** or **32** in methanol (6 mL), 10% palladium on activated carbon (7 mg) was added and the mixture was hydrogenated overnight. The catalyst was filtered off and the filtrate was concentrated under reduced pressure. The residue was

purified by column chromatography on silica (5→10% ethyl acetate/hexane) to give the product **33**, **34**, **35** or **36**.

General Procedure for the Synthesis of Compounds **37**, **38**, **39** and **40**

To a stirred solution of the alcohol **33**, **34**, **35** or **36** (1 eq) and 2,6-lutidine (3.6 - 4 eq) in anhydrous methylene chloride (3 mL), *tert*-butyldimethylsilyl trifluoromethanesulfonate (1.8 - 2 eq) was added at -20 °C. The reaction mixture was stirred at 0 °C for 1 h. It was quenched with water and extracted with methylene chloride. Combined organic phases were washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (3% ethyl acetate/hexane) to give the product **37**, **38**, **39** or **40**.

General Procedure for the Synthesis of Compounds **41**, **42**, **43** and **44**

To a stirred solution of the benzoate **37**, **38**, **39** or **40** in anhydrous ethanol (10 mL), a solution of sodium hydroxide in anhydrous ethanol (2.5M, 2 mL) was added. The reaction mixture was refluxed for 18 h. It was cooled to room temperature, neutralized with 5% aqueous solution of HCl and extracted with methylene chloride. Combined organic phases were washed with a saturated aqueous NaHCO₃ solution, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (5→10% ethyl acetate/hexane) to give the alcohol **41**, **42**, **43** or **44**.

General Procedure for the Synthesis of Compounds **45**, **46**, **47** and **48**

To a stirred solution of 4-methylmorpholine N-oxide (3.2 - 3.6 eq) in anhydrous methylene chloride (0.5 mL), pulverized molecular sieves A4 (ca. 60 mg) were added and the mixture was stirred for 15 min. Then tetrapropylammonium perruthenate (0.13 - 0.22 eq) was added, followed by a solution of the alcohol **41**, **42**, **43** or **44** (1 eq) in anhydrous methylene chloride (300 + 300 µL). The resulting dark mixture was stirred at room temperature for 1 h, then it was filtered through a silica Sep-Pak, which was further washed with methylene chloride. After evaporation of the solvent the ketone **45**, **46**, **47** or **48** was obtained.

General Procedure for the Synthesis of Compounds **50**, **51**, **52** and **53**

To a stirred solution of the phosphine oxide **49** (2.5 - 3.8 eq) in anhydrous THF (500 µL), a solution of phenyllithium (3.3 - 4.6 eq) was added at -20 °C under argon. The mixture was stirred for 30 min and then cooled to -78 °C. A pre-cooled solution of the Grundmann's type ketone **45**, **46**, **47** or **48** (1 eq) in anhydrous THF (200 + 100 µL) was added *via* cannula and the reaction mixture was stirred for 4 h at -78 °C. Then the reaction mixture was stirred at 4 °C for 19 h. Ethyl acetate (20 mL) was added and the organic phase was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified on a Waters silica Sep-Pak cartridge (0→2% ethyl acetate/hexane) to give the protected vitamin D compound **50**, **51**, **52** or **53**.

General Procedure for the Synthesis of Compounds **5**, **6**, **7** and **8**

To a solution of the protected vitamin **50**, **51**, **52** or **53** in THF (5 mL) and acetonitrile (4 mL), a solution of aqueous 48% HF in acetonitrile (1:9 ratio, 2 mL) was added at 0 °C and the resulting mixture was stirred at room temperature for 6 h. The reaction was quenched with a saturated aqueous NaHCO₃ solution and extracted with ethyl acetate. Combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, concentrated under reduced pressure. The residue was purified on a Waters silica Sep-Pak cartridge (10→30% ethyl acetate/hexane) to give the crude products. Final purifications of the vitamin D compounds were performed by straight phase HPLC (15% 2-propanol/hexane; 4 mL/min; 9.4 mm × 25 cm Zorbax Sil column), followed by reversed-phase HPLC (15% water/

methanol; 3 mL/min; 9.4 mm × 25 cm Zorbax Eclipse XDB-C18 column) to give the analytically pure 19,26-dinorvitamin D analogs **5**, **6**, **7** or **8**.

General Procedure for the Synthesis of Compounds **9**, **10**, **11**, **12**, **13**, **14**, **15** and **16**

Tris(triphenylphosphine)rhodium (I) chloride (1.0 - 1.5 eq) was added to dry benzene (5 mL) presaturated with hydrogen (15 min). The mixture was stirred at room temperature until a homogeneous solution was formed (ca. 25 min). A solution of the analog **5**, **6**, **7** or **8** (1 eq) in dry benzene (3+1 mL) was added and the reaction was allowed to proceed under a continuous stream of hydrogen for 4 h. The solvent was removed under reduced pressure, the residue was redissolved in hexane/ethyl acetate (1:1) and applied on a Waters silica Sep-Pak cartridge (2 g). A mixture of 2-methyl vitamins was eluted with the same solvent system. A mixture of compounds was further purified by HPLC (9.4 × 250 mm Zorbax-Sil column, 4 mL/min) using a hexane/2-propanol (85:15) solvent system. The separation of 2 α -methyl analogs **9**, **10**, **13** or **14**, from the 2 β -methyl ones **11**, **12**, **15** or **16**, was achieved by reversed-phase HPLC (9.4 × 250 mm Zorbax RX-C18 column, 3 mL/min) using a methanol/water (85:15) solvent system.

Biological Studies

1. **In vitro studies.** VDR binding, HL-60 differentiation and 24-hydroxylase transcription assays were performed as previously described.¹⁹
2. **In vivo studies.** Bone calcium mobilization and intestinal calcium transport were performed as previously described.¹⁹ Briefly, weanling rats were made vitamin D-deficient by housing under lighting conditions that block vitamin D production in the skin. In addition, the animals were fed a diet devoid of vitamin D and alternating levels of calcium. Experimental compounds were administered intraperitoneally once per day for four consecutive days. Twenty-four hours after the last dose was given, the blood was collected and everted gut sacs prepared. Calcium was measured in the blood and two different intestinal compartments using atomic absorption spectrometry. Each study was comprised of at least 5-6 animals/experimental group and was controlled with a vehicle group (5% ethanol:95% propylene glycol) and one or more positive control groups (1,25(OH)₂D₃).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The work was supported in part by funds from the Wisconsin Alumni Research Foundation. We gratefully acknowledge Jean Pahl, Julia Zella and Jennifer Vaughan for carrying out the *in vitro* studies, and Heather Neils, Shinobu Miyazaki and Xiaohong Ma for conducting the *in vivo* studies. We thank Dr. Mark Anderson for his assistance in recording NMR spectra. This study made use of the National Magnetic Resonance Facility at Madison, which was supported by the NIH grants P41RR02301 (BRTP/NCRR) and P41GM66326 (NIGMS). Additional equipment was purchased with funds from the University of Wisconsin, the NIH (RR02781, RR08438), the NSF (DMB-8415048, OIA-9977486, BIR-9214394), and the USDA.

References

1. Feldman, D.; Pike, J.W.; Glorieux, F.H., editors. Vitamin D. Second. Elsevier Academic Press; Burlington: 2005.
2. Jones G, Strugnelli SA, DeLuca HF. Current understanding of the molecular action of vitamin D. *Physiol Rev.* 1998; 78:1193–1231. [PubMed: 9790574]

3. Norman, AW.; Bouillon, R.; Thomasset, M., editors. Vitamin D, a pluripotent steroid hormone: Structural studies, molecular endocrinology and clinical applications. Walter de Gruyter; Berlin: 1994.
4. Plum LA, DeLuca HF. The functional metabolism and molecular biology of vitamin D action. *Clin Rev Bone Miner Metab.* 2009; 7:20–41.
5. Suda T, Shinki T, Takahashi N. The role of vitamin D in bone and intestinal cell differentiation. *Annu Rev Nutri.* 1990; 10:195–211.
6. Suda T. The role of $1\alpha,25$ -dihydroxyvitamin D₃ in the myeloid cell differentiation. *Proc Soc Exp Biol Med.* 1989; 191:214–220. [PubMed: 2662197]
7. Ostrem VK, DeLuca HF. The vitamin D-induced differentiation of HL-60 cells: Structural requirements. *Steroids.* 1987; 49:73–102. [PubMed: 3331848]
8. Abe E, Miyaura C, Sakagami H, Takeda M, Konno K, Yamazaki T, Yoshiki S, Suda T. Differentiation of mouse myeloid leukemia cells induced by $1\alpha,25$ -dihydroxyvitamin D₃. *Proc Natl Acad Sci USA.* 1981; 78:4990–4994. [PubMed: 6946446]
9. Lemire JM. Immunomodulatory role of $1,25$ -dihydroxyvitamin D₃. *J Cell Biochem.* 1992; 49:26–31. [PubMed: 1644850]
10. Brown AJ, Slatopolsky E. Vitamin D analogs: Therapeutic applications and mechanisms for selectivity. *Molecular Aspects of Medicine.* 2008; 29:433–452. [PubMed: 18554710]
11. Posner GH, Kahraman M. Organic chemistry of vitamin D analogues (deltanoids). *Eur J Org Chem.* 2003:3889–3895.
12. Grzywacz P, Plum LA, Sicinski RR, Clagett-Dame M, DeLuca HF. Methyl substitution of the 25-hydroxy group on 2-methylene-19-nor- $1\alpha,25$ -dihydroxyvitamin D₃ (2MD) reduces potency but allows bone selectivity. *Arch Biochem Biophys.* 2007; 460:274–284. [PubMed: 17094936]
13. Grzywacz P, Plum LA, Sicinska W, Sicinski RR, Prah J, DeLuca HF. 2-Methylene analogs of 1α -hydroxy-19-norvitamin D₃: synthesis, biological activities and docking to the ligand binding domain of the rat vitamin D receptor. *J Steroid Biochem Mol Biol.* 2004; 89-90:13–17. [PubMed: 15225739]
14. (a) Shevde NK, Plum LA, Clagett-Dame M, Yamamoto H, Pike JW, DeLuca HF. A potent analog of $1\alpha,25$ -dihydroxyvitamin D₃ selectively induces bone formation. *Proc Natl Acad Sci USA.* 2002; 99:13487–13491. [PubMed: 12374862] (b) Plum LA, Fitzpatrick LA, Ma X, Binkley NC, Zella JB, Clagett-Dame M, DeLuca HF. 2MD, a new anabolic agent for osteoporosis treatment. *Osteoporosis Int.* 2006; 17:704–715.
15. Lythgoe B, Moran TA, Nambudiry MEN, Ruston S. Allylic phosphine oxides as precursors of conjugated dienes of defined geometry. *J Chem Soc Perkin Trans I.* 1976:2386–2390.
16. Maryanoff BE, Reitz AB. The Wittig olefination reaction and modifications involving phosphoryl-stabilized carbanions. Stereochemistry, mechanism, and selected synthetic aspects. *Chem Rev.* 1989; 89:863–927.
17. Fall Y, Vitale C, Mourino A. An efficient synthesis of the 25-hydroxy Windaus-Grundmann ketone. *Tetrahedron Lett.* 2000; 41:7337–7340.
18. Ley SV, Norman J, Griffith WP, Marsden SP. Tetrapropylammonium perruthenate, Pr₄NRuO₄, TPAP: a catalytic oxidant for organic synthesis. *Synthesis.* 1994:639–666.
19. (a) Glebocka A, Sicinski RR, Plum LA, Clagett-Dame M, DeLuca HF. New 2-alkylidene $1\alpha,25$ -dihydroxy-19-norvitamin D₃ analogues of high intestinal activity: synthesis and biological evaluation of 2-(3'-alkoxypropylidene) and 2-(3'-hydroxypropylidene) derivatives. *J Med Chem.* 2006; 49:2909–2920. [PubMed: 16686534] (b) Chiellini G, Grzywacz P, Plum LA, Barycki R, Clagett-Dame M, DeLuca HF. Synthesis and biological properties of 2-methylene-19-nor-25-dehydro- 1α -hydroxyvitamin D₃-26,23-lactones – weak agonists. *Bioorg Med Chem.* 2008; 16:8563–8573. [PubMed: 18722130]

Figure 1. Chemical structures of $1\alpha,25$ -dihydroxyvitamin D₃ (calcitriol, **1**) and 19-nor analogs (**2**, **3**, **4**, **5**, **6**, **7**, **8**, **9**, **10**, **11**, **12**, **13**, **14**, **15** and **16**).

Figure 2.
X-ray crystal structure of (20*R*,25*S*)-2-methylene-19,26-dinor-1 α ,25-dihydroxyvitamin D₃ (5).

Figure 3.

Serum calcium levels of vitamin D-deficient rats on a 0.02% calcium diet and given vehicle or vehicle plus the indicated compound each day for 4 days as an intraperitoneal injection. Serum was harvested 24 hours after the last dose.

NOTE: Dose ranging studies were performed with these compounds, but only the highest dose levels tested are shown in order to highlight the differences and make it easier for the reader.

Scheme 1.

Synthesis of the Grundmann ketones **45**, **46**, **47** and **48**.

Reagents: i) SO_3 pyridine, Et_3N , DMSO, CH_2Cl_2 ; ii) 1. **21** or **22**, $n\text{-BuLi}$, THF, 2. **19** or **20**, THF; iii) H_2 , Pd/C, MeOH; iv) TBSOTf, 2,6-lutidine, CH_2Cl_2 ; v) 1. KOH, EtOH, 2. aq. HCl; vi) TPAP, NMO, molecular sieves 4Å, CH_2Cl_2 .

Scheme 2.

Synthesis of the phosphonium iodides **21** and **22**.

Reagents: i) 1. TsCl, DMAP, Et₃N, CH₂Cl₂, 2. TESOTf, 2,6-lutidine, CH₂Cl₂; ii) KI, acetone; iii) Ph₃P, MeCN.

Scheme 3.

Syntheses of the vitamin D analogs **5**, **6**, **7**, **8**, **9**, **10**, **11**, **12**, **13**, **14**, **15** and **16**.

Reagents: i) 1. **49**, PhLi, THF, 2. **45**, **46**, **47** or **48**, THF; ii) aq. HF, THF, MeCN; iii) H₂, (Ph₃P)₃RhCl, PhH.

Table 1

VDR Binding Properties,^a HL-60 Differentiating Activities,^b and Transcriptional Activities^c of the Vitamin D Analogs (5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16)

Compound	Structure of a side chain (R)	Compd No.	VDR binding		HL-60 differentiation		24-OHase transcription	
			K _i	ratio	EC ₅₀	ratio	EC ₅₀	ratio
1α,25-(OH) ₂ D ₃	-	1	1 × 10 ⁻¹⁰ M	1	2 × 10 ⁻⁹ M	1	2 × 10 ⁻¹⁰ M	1
	4	1 × 10 ⁻¹⁰ M	1	8 × 10 ⁻¹¹ M	0.04	7 × 10 ⁻¹² M	0.035
	5	1 × 10 ⁻¹⁰ M	1	2 × 10 ⁻⁹ M	1	4 × 10 ⁻¹⁰ M	2
	6	6 × 10 ⁻¹¹ M	0.6	6 × 10 ⁻¹⁰ M	0.3	6 × 10 ⁻¹¹ M	0.3
	7	1 × 10 ⁻¹⁰ M	1	1 × 10 ⁻⁹ M	0.5	2 × 10 ⁻¹⁰ M	1
	8	9 × 10 ⁻¹¹ M	0.9	9 × 10 ⁻¹¹ M	0.045	1 × 10 ⁻¹¹ M	0.05
	9	2 × 10 ⁻¹⁰ M	2	5 × 10 ⁻⁹ M	2.5	6 × 10 ⁻¹⁰ M	3
10	1 × 10 ⁻¹⁰ M	1	4 × 10 ⁻¹⁰ M	0.2	8 × 10 ⁻¹¹ M	0.4
	13	3 × 10 ⁻¹⁰ M	3	2 × 10 ⁻⁹ M	1	4 × 10 ⁻¹⁰ M	2
	14	8 × 10 ⁻¹¹ M	0.8	1 × 10 ⁻¹⁰ M	0.05	2 × 10 ⁻¹¹ M	0.1
	11	5 × 10 ⁻⁹ M	50	1 × 10 ⁻⁷ M	50	3 × 10 ⁻⁸ M	150
12	5 × 10 ⁻¹⁰ M	5	2 × 10 ⁻⁸ M	10	7 × 10 ⁻⁹ M	35
	15	2 × 10 ⁻⁹ M	20	6 × 10 ⁻⁸ M	30	2 × 10 ⁻⁸ M	100
	16	4 × 10 ⁻¹⁰ M	4	6 × 10 ⁻⁹ M	3	1 × 10 ⁻⁹ M	5

^aCompetitive binding of 1α,25-(OH)₂D₃ (1) and the synthesized vitamin D analogs to the full-length recombinant rat vitamin D receptor. The K_i values are derived from dose-response curves and represent the inhibition constant when radiolabeled 1α,25-(OH)₂D₃ is present at 1 nM and a K_d of 0.2 nM is used. The binding ratio is the average ratio of the analog K_i to the K_i for 1α,25-(OH)₂D₃.

^b induction of differentiation of HL-60 promyelocytes to monocytes by $1\alpha,25-(\text{OH})_2\text{D}_3$ and the synthesized vitamin D analogs. Differentiation state was determined by measuring the percentage of cells reducing nitro blue tetrazolium (NBT). The EC_{50} values are derived from dose-response curves and represent the analog concentration capable of inducing 50% maturation. The differentiation activity ratio is the average ratio of the analog EC_{50} to the EC_{50} for $1\alpha,25-(\text{OH})_2\text{D}_3$.

^c Transcriptional assay in rat osteosarcoma cells stably transfected with a 24-hydroxylase gene reporter plasmid. The EC_{50} values are derived from dose-response curves and represent the analog concentration capable of increasing the luciferase activity by 50%. The luciferase activity ratio is the average ratio of the EC_{50} for the analog to the EC_{50} for $1\alpha,25-(\text{OH})_2\text{D}_3$. All the experiments were carried out in duplicate on at least two different occasions.

Table 2

Summary of intestinal Ca transport.

Compound	Structure of a side chain (R)	Compd No.	Dose level (pmol/rat/day)	Intestinal Ca transport (increase in S/M ratio* compared to Vehicle)
-	1	260	3.2
	4	260	4.0
	5	260	1.5
	6	260	1.4
	7	260	1.6
	8	260	2.8
	9	35100	2.4
	10	7020	3.0
13	35100	3.0
	14	7020	3.2
	11	35100	1.4
	15	35100	1.6
16	21060	1.6

* S/M Ratio = the amount of calcium found in the serosal compartment divided by the amount of calcium present in the mucosal compartment